Please assess the completion status of the following clinical trial:

Trial Title: A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* For low-risk participant arms 9-11 only: Are greater than or equal to (≥)18 and less than (\<)65 years of age at the time of randomization and do not have the risk factors defined in the bullet point directly below~* For high-risk participant arms 12 and 13 only:~  -- Are ≥18 years of age and satisfy at least one of the following risk factors at the time of screening~ * Are ≥65 years of age~ * Have a body mass index (BMI) ≥ 35~ * Have chronic kidney disease~ * Have type 1 or type 2 diabetes~ * Have immunosuppressive disease~ * Are currently receiving immunosuppressive treatment, or~ * Are ≥55 years of age AND have~    * cardiovascular disease, OR~   * hypertension, OR~   * chronic obstructive pulmonary disease or other chronic respiratory disease~* For high-risk participant arms 12 and 13 only:~  * Are 12-17 years of age (inclusive) AND satisfy at least one of the following risk factors at the time of screening~    * Have a BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm~   * Have sickle cell disease~   * Have congenital or acquired heart disease~   * Have neurodevelopmental disorders, for example, cerebral palsy~   * Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)~   * Have asthma or reactive airway or other chronic respiratory disease that requires daily medication for control~   * Have type 1 or type 2 diabetes~   * Have chronic kidney disease~   * Have immunosuppressive disease, or~   * Are currently receiving immunosuppressive treatment.~For high-risk participants arm 14 only:~* Are ≥12 years of age and satisfy at least one of the following risk factors at the time of screening Are ≥65 years of age~* Are adults (≥18 years of age) with BMI \>25 kg/m2 , or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts~* Have chronic kidney disease~* Have type 1 or type 2 diabetes~* Have immunosuppressive disease~* Are currently receiving immunosuppressive treatment~* Have cardiovascular disease (including congenital heart disease) or hypertension~* Have chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma \[moderate-to-severe\], interstitial lung disease, cystic fibrosis and pulmonary hypertension)~* Have sickle cell disease~* Have neurodevelopmental disorder (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)~* Have a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation \[not related to COVID-19\]~* Are currently not hospitalized~* Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion, nasal congestion or runny nose, new loss of smell, chills~* Must have sample taken for test confirming viral infection no more than 3 days prior to starting the drug infusion~* Are men or non-pregnant women who agree to contraceptive requirements~* Understand and agree to comply with planned study procedures~* Agree to the collection of nasopharyngeal swabs and venous blood~* The participant or legally authorized representative give signed informed consent and/or assent~Exclusion Criteria:~* For low-risk participants only: BMI ≥35~* Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) \<300, respiratory rate ≥30 per minute, heart rate ≥125 per minute~* Require mechanical ventilation or anticipated impending need for mechanical ventilation~* Have known allergies to any of the components used in the formulation of the interventions~* Have hemodynamic instability requiring use of pressors within 24 hours of randomization~* Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention~* Have any co-morbidity requiring surgery within \<7 days, or that is considered life-threatening within 29 days~* Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study~* Have a history of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test prior to the one serving as eligibility for this study~* Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing~* Have received treatment with a SARS-CoV-2 specific monoclonal antibody~* Have a history of convalescent COVID-19 plasma treatment~* For low-risk arms only: have received a SARS-CoV-2 vaccine or have participated in a previous SARS-CoV-2 vaccine study and are currently blinded to treatment allotment~* Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed~* Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study~* Are pregnant or breast feeding~* Are investigator site personnel directly affiliated with this study~* Have body weight \<40 kilograms

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Pbo) (Type: PLACEBO_COMPARATOR): Treatment 1: Pbo administered intravenously (IV).~Treatment 8: Pbo For 700 mg Bamlanivimab (BAM) + 500 mg VIR-7831 (Amendment (C-e)) administered IV.~Treatment 11: Pbo For 175 mg Bebtelovimab (BEB) \& 700 mg BAM +1400 mg Etesevimab ( ETE) +175 mg BEB (Low Risk Participants) administered IV.~Pooled Placebo (Addendum 4, IV) administered IV.~Pooled Placebo (Addendum 4, SC) administered SC.
- BAM + ETE (Type: EXPERIMENTAL): Treatment 2: 175 mg BAM +350 mg ETE administered IV.~Treatment 3: 700 mg BAM +1400 mg ETE administered IV.~Treatment 4: 2800 mg BAM +2800 mg ETE administered IV.~Treatment 6: 350 mg BAM +700 mg ETE administered IV.~Unintentional Dosing: 700 mg BAM +700 mg ETE administered IV.~700 mg BAM + 1400 mg ETE 30-min (Addendum (2)) administered IV.~700 mg BAM + 1400 mg ETE 15-min (Addendum (2)) administered IV.
- BAM (Type: EXPERIMENTAL): Treatment 5: 700 mg BAM administered IV.~700 mg BAM 15-min (Addendum (2)) administered IV.
- BAM + VIR-7831 (Type: EXPERIMENTAL): Treatment 7: 700 mg BAM + 500 mg VIR-7831 (Amendment (C-e)) administered IV.
- BEB (Type: EXPERIMENTAL): Treatment 9: 175 mg BEB (Amendment (f), Low Risk Participants) administered IV.~Treatment 12: 175 mg BEB (Amendment (f), High Risk Participants) administered IV.~70 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.~175 mg BEB 140 mg/Min (Addendum 4, IV) administered IV.~175 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.~1750 mg BEB 350 mg/Min (Addendum 4, IV) administered IV.~280 mg BEB (Addendum 4, SC) administered SC.~560 mg BEB (Addendum 4, SC) administered SC.
- BAM+ ETE + BEB (Type: EXPERIMENTAL): Treatment 10: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), Low Risk Participants) administered IV.~Treatment 13: 700 mg BAM +1400 mg ETE +175 mg BEB (Amendment (f), High Risk Participants) administered IV.~Treatment 14: 700 mg BAM + 1400 mg ETE + 175 mg BEB(Amendment (g), High Risk, Updated Centers for Disease Control and Prevention (CDC) Criteria) administered IV.~175/700/1400 mg BAM + ETE + BEB 350 mg/Min (Addendum 4, IV) administered IV.

Based on this trial design, predict the completion outcome and termination type (if applicable).